Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
NEW YORK, Aug. 16, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Ocular Therapeutix, Inc. ("Ocular Therapeutix") (NASDAQ:OCUL) securities between March 10, 2016 and July 11, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/ocular-therapeutix-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Ocular failed to adequately address issues identified in the First Form 483; (ii) Ocular’s re-submitted NDA would not be approved by the July 19, 2017 PDUFA date because the Company could not timely and adequately address the FDA-identified manufacturing and control issues; (iii) Ocular’s continued manufacturing issues imperil the approval of DEXTENZA; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Ocular Therapeutix you have until September 5, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/ocular-therapeutix-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
